Christopher Paul James Wightman
Non-Executive Chairman
Mr. Wightman joined PuriCore in 1998 as a Non-Executive Director and was appointed Non-Executive Chairman of the Board of Directors in August 2002. Mr. Wightman is chairman or director of a number of other private UK companies. He previously spent 14 years in the investment banking industry with Goldman Sachs, Bankers Trust, NatWest, and NationsBank. He read law at Nottingham University before joining Arthur Andersen & Co., where he qualified with the Institute of Chartered Accountants. Mr. Wightman is a member of the Nominations Committee.
Gregory Todd Bosch
Chief Executive Officer
Mr. Bosch joined PuriCore in November 2004 as Chief Executive Officer. Prior to joining PuriCore, Mr. Bosch held a variety of management and leadership positions with Baxter International during his 19-year tenure. Most recently, he was Vice President and General Manager of Baxter's BioSurgery division, which experienced growth from $40 million in 1998 to more than $220 million in 2004 under his leadership. He had international assignments in Austria and Switzerland and he was a board member of Baxter AG, a company with more than 2,500 employees. Mr. Bosch was named Life Sciences CEO of the Year by the Eastern Technology Council's Enterprise Awards for the Greater Philadelphia region in 2006. Mr. Bosch received his BA from Duke University and his MBA from DePaul University. Mr. Bosch is a member of the PuriCore Nominations Committee.
Timothy Bruce Anderson
Independent Non-Executive Director
Mr. Anderson joined PuriCore in September 2006 as an Independent Non-Executive Director. He held various executive management positions from 1972 to 2002 at Baxter International (NYSE: BAX), a leading US medical technology company, including Senior Vice President of Strategy and Business Development; President, Biotech Group; and Group Vice President and Chairman, Baxter Europe. Mr. Anderson is also currently a Director of Cerus Corporation (NASDAQ: CERS) and Lake Forest Hospital. Mr. Anderson is a member of the PuriCore Audit Committee.
Joseph William Birkett
Senior Independent Non-Executive Director
Mr. Birkett joined PuriCore in 1999 as an Independent Non-Executive Director. On January 31, 2008, he was appointed Senior Independent Non-Executive Director. Mr. Birkett is an independent consultant and investor. He is former Chairman of Chelford Group plc, an AIM-listed supply chain software company, and former Non-Executive Director of Monument Securities, Ltd. His career was in finance and global investment banking before forming and running two independent venture capital firms in the 1980s and 1990s. Following a BSc in Economics from Sheffield University, he qualified as an FCA with Touche Ross (now Deloitte & Touche LLP). Mr. Birkett is a member of the PuriCore Audit and Nominations Committees.
Michael Dimitrios Sapountzoglou
Non-Executive Director
Mr. Sapountzoglou joined PuriCore in 1999 as a Non-Executive Director. Mr Sapountzoglou brings more than 20 years of investment and finance experience and is currently the Finance Director for Metrostar Management Corp., the shipping arm of the Angelopoulos group, and serves as the corporate finance and investment adviser for the group's other global investment activities. Prior to this, he was a co-founder of Gamma Research, a financial advisory firm focusing on European and Eastern European markets. He was also the Investment Manager for Star Maritime S.A., a private company based in Monte Carlo and part of the Livanos Shipping Group, where he managed and oversaw the Group's proprietary investment portfolios. He is also an investment advisor to Gacita Limited. Mr. Sapountzoglou is a member of the PuriCore Remuneration and Nominations Committees.
James Walsh, PhD
Independent Non-Executive Director
Dr. Walsh joined PuriCore in September 2006 as an Independent Non-Executive Director. He has 20 years of general management experience in the healthcare industry with particular experience in diagnostics. He is Non-Executive Director with Trinity Biotech Plc (NASDAQ: TRIB) and a member of the Advisory Board for Kemel Capital. He is also CEO of Stokes Bio Ltd., an Irish-based microfluidics company working in the area of molecular diagnostics. Dr Walsh also holds Non-Executive Director positions with a number of early-stage companies in the life science areas. Previously Dr. Walsh was Managing Director of Cambridge Diagnostics Ltd., a wholly owned subsidiary of Inverness Medical Innovations Inc (AMEX: IMA). Dr Walsh is a graduate of the National University of Ireland and holds a Doctorate in Inorganic Chemistry and Post Doctorate qualifications in Immunochemistry. Dr. Walsh is a member of the PuriCore Remuneration Committee.